CLOs on the Move

Universal Pediatrics

www.universalpediatrics.com

 
Universal Pediatrics is a company that provides in-home healthcare and private duty nursing services for children and young adults with serious medical conditions.
  • Number of Employees: 100-250
  • Annual Revenue: $10-50 Million

Executives

Name Title Contact Details

Similar Companies

Clean Plates

Clean Plates Omnimedia LLC is a premier media company focused on the new health and wellness food culture, with products that include digital, print and social media, as well as mobile apps. Begun in 2009 by Jared Koch–a certified nutritionist from the Institute for Integrative Nutrition and the Global Institute for Alternative Medicine—Clean Plates provides an integrative approach through food, sustainability, and wellness to optimize your health and happiness, thereby helping you perform at your peak—whether on the go, in the kitchen or dining out.

Shiongi Inc

Shiongi Inc is a Florham Park, NJ-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Country Pines Retirement Home

Country Pines Retirement Home is a Clearfield, UT-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

PharmaCann

PharmaCann is Improving lives, committed to truth and transparency, bringing the cannabis industry to scale.

Kymera Therapeutics

Kymera is a biopharmaceutical company focused on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body’s own natural protein degradation system. Kymera’s proprietary targeted protein degradation platform, called Pegasus, enables us to discover highly selective small molecule protein degraders with activity against disease-causing proteins throughout the body. We believe that our small molecule protein degraders have significant advantages over existing therapies and allow us to address a large portion of the human genome that was previously intractable with traditional modalities. Kymera focuses on biological pathways that have been clinically validated but where key biological nodes/proteins have not been drugged or have been inadequately drugged. To date, we have utilized our Pegasus platform to design novel protein degraders focused in the areas of immunology-inflammation and oncology, and continue to apply our platform’s capabilities to additional therapeutic areas.